SCHEMBL64064

SCHEMBL64064

CC(C)S(=O)(=O)N1CCCC1C(=O)NC12CCC(CC1)Cn1c2nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.49
CYP2C9 P11712 3/20 0.44
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
GLA P06280 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 3/20 0.36
F2 P00734 2/20 0.36
KCNE1 P15382 1/20 0.36
CCR1 P32246 1/20 0.36
KCNQ1 P51787 1/20 0.36
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
POLB P06746 1/20 0.35
CALCA P06881 1/20 0.35
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL62604 0.92 KCNH2 (0.51) KCNH2CYP2C9MAPTTDP1GLA
SCHEMBL63362 0.92 KCNH2 (0.51) KCNH2CYP2C9MAPTTDP1GLA
SCHEMBL62837 0.91 KCNH2 (0.51) KCNH2CYP2C9MAPTGLASMN1; SMN2
SCHEMBL64403 0.90 CYP2C9 (0.49) KCNH2CYP2C9MAPTTDP1GLA
SCHEMBL64605 0.90 KCNH2 (0.49) KCNH2CYP2C9MAPTTDP1GLA
SCHEMBL64388 0.90 KCNH2 (0.49) KCNH2CYP2C9MAPTGLASMN1; SMN2
SCHEMBL64162 0.90 KCNH2 (0.49) KCNH2CYP2C9MAPTGLASMN1; SMN2
SCHEMBL64067 0.90 KCNH2 (0.49) KCNH2CYP2C9MAPTGLASMN1; SMN2
SCHEMBL63630 0.89 KCNH2 (0.46) KCNH2CYP2C9GLAALDH1A1F2
SCHEMBL63411 0.88 KCNH2 (0.50) KCNH2CYP2C9MAPTGLASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885MAPT 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.